Long-term results of CT-guided percutaneous radiofrequency ablation of inoperable patients with stage Ia non-small cell lung cancer: A retrospective cohort study. (May 2018)

• Record Type: Journal Article
• Authors: Huang, Bing-Yang; Li, Xin-Min; Song, Xiao-Yong; Zhou, Jun-Jun; Shao, Zhuang; Yu, Zhi-Qi; Lin, Yi; Guo, Xin-yu; Liu, Da-Jiang; Li, Lu
• Is Part Of: International journal of surgery. Volume 53(2018)
• Page Start: 143
• Page End: 150
• Publication Date: 2018-05
• Subjects: Ia non-small cell lung cancer -- Radiofrequency ablation -- Minimally invasive treatment; Surgery -- Periodicals; Surgical Procedures, Operative -- Periodicals; 617.005
• DOI: 10.1016/j.ijsu.2018.03.034
• Languages: English
• ISSNs: 1743-9191

Abstract

Abstract: Background: This study was performed to retrospectively evaluate the 10-year overall survival (OS), progression-free survival (PFS), and local control rates of patients with inoperable stage Ia non-small cell lung cancer (NSCLC) who underwent computed tomography (CT)-guided radiofrequency ablation (RFA) in a single center. Materials and methods: Fifty patients with inoperable NSCLC underwent RFA between 2004 and 2016. Thoracic surgeons evaluated the patients and performed RFA under CT guidance. Follow-up CT and positron emission tomography/CT scans were obtained. Local control rates and recurrence patterns were analyzed. Results: Seventy-three lesions in 50 patients (M:F = 22:28; median age: 73 years; range: 52–82 years) were treated with CT-guided RFA. The mean lesion size was 2.2 cm (range: 1–3 cm). No procedure-related deaths occurred. Low-grade fever was the most common post-ablation complication, with an incidence rate of 36%. The 1-, 2-, 3-, 5-, and 10-year OS rates of patients with Ia NSCLC were 96.0%, 86.5%, 67.1%, 36.3%, and 1%, respectively, and the 1-, 2-, 3-, and 5-year PFS rates were 94.0%, 77.5%, 43.5%, and 10.8%, respectively. The most common pattern of recurrence was local, and 15 patients with recurrence were treated with repeat RFA. Tumor size <2.0 cm was associated with a significantly improved 3-year survival rate of 78.9%. Conclusion: CT-guided RFA is feasible and well tolerated by inoperable patients with inoperable stage Ia NSCLC. Highlights: CT-guided RFA is feasible and well tolerated for inoperable stage Ia NSCLC patients. The 1-, 2-, 3-, 5-, and 10-year OS rates were 96.0%, 86.5%, 67.1%, 36.3%, and 1%. The 1-, 2-, 3-, and 5-year PFS rates were 94.0%, 77.5%, 43.5%, and 10.8%.